AbbVie Receives Positive CHMP Opinion for VENCLYXTO® as a Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic Leukemia
- Friday, January 31, 2020, 7:16
- PR Newswire
- Add a comment
NORTH CHICAGO, Ill., Jan. 31, 2020 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for VENCLYXTO®…
About the Author
admin has written 20022 stories on this site.